Voyager Therapeutics (VYGR) EBIT Margin (2015 - 2026)

Voyager Therapeutics has disclosed EBIT Margin across 12 years of filings, most recently posting 1167.37% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 1167.37%, down 63364.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 348.46% (down 19659.0% YoY), and the FY2025 annual result was 326.56%, down 22245.0% from the prior year.
• EBIT Margin came in at 1167.37% for Q1 2026 at Voyager Therapeutics, down from 194.69% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 1584.71% in Q4 2022 to a low of 3244.68% in Q1 2022.
• The 5-year median for EBIT Margin is 228.31% (2025), against an average of 534.93%.
• Across the five-year window, EBIT Margin tumbled 285106 bps in 2022 and jumped 332634 bps in 2023, its largest moves.
• Voyager Therapeutics' EBIT Margin stood at 1584.71% in 2022, then slumped by 103 bps to 44.24% in 2023, then slumped by 1274 bps to 607.82% in 2024, then jumped by 68 bps to 194.69% in 2025, then sank by 500 bps to 1167.37% in 2026.
• The last three EBIT Margin figures came in at 1167.37% (Q1 2026), 194.69% (Q4 2025), and 228.31% (Q3 2025), per Business Quant data.